Nekkab Narimane, Malinga Josephine, Braunack-Mayer Lydia, Kelly Sherrie L, Miller R Scott, Penny Melissa A
Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
University of Basel, Basel, Switzerland.
Commun Med (Lond). 2023 Mar 25;3(1):41. doi: 10.1038/s43856-023-00274-0.
Global progress against malaria has stagnated and novel medical interventions to prevent malaria are needed to fill gaps in existing tools and improve protection against infection and disease. Candidate selection for next-generation interventions should be supported by the best available evidence. Target product profiles and preferred product characteristics play a key role in setting selection criteria requirements and early endorsement by health authorities. While clinical evidence and expert opinion often inform product development decisions, integrating modelling evidence early and iteratively into this process provides an opportunity to link product characteristics with expected public health outcomes. Population models of malaria transmission can provide a better understanding of which, and at what magnitude, key intervention characteristics drive public health impact, and provide quantitative evidence to support selection of use-cases, transmission settings, and deployment strategies. We describe how modelling evidence can guide and accelerate development of new malaria vaccines, monoclonal antibodies, and chemoprevention.
全球抗击疟疾的进展已陷入停滞，需要新型医学干预措施来填补现有工具的空白，并加强对感染和疾病的防护。下一代干预措施的候选选择应得到现有最佳证据的支持。目标产品简介和优选产品特性在设定选择标准要求以及获得卫生当局的早期认可方面发挥着关键作用。虽然临床证据和专家意见常常为产品开发决策提供依据，但将建模证据尽早且反复地纳入这一过程，能为将产品特性与预期公共卫生结果相联系提供契机。疟疾传播的人群模型有助于更好地理解哪些关键干预特性会产生公共卫生影响、影响程度如何，并提供量化证据以支持用例、传播环境和部署策略的选择。我们阐述了建模证据如何指导并加速新型疟疾疫苗、单克隆抗体和化学预防方法的开发。
